AORT logo

ARTIVION INC

AORTNYSE
πŸ† #2409 by market capEarnings Nov 5US Equity
$22.86β–Ό $0.09 (βˆ’0.39%)
πŸŒ™ After hours$23.31β–² 1.97%Regular close Β· extended-hours price shown
πŸ””
Track AORT
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 0.4%
7dβ–Ό 5.3%
14dβ–Ό 9.9%
30dβ–Ό 14.6%
ytdβ–Ό 50.0%
1yβ–Ό 45.5%
🏦Market Cap
$1.11B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+13.6%
Healthy
πŸ“ŠGross Margin
62.8%
High
πŸ’΅FCF Margin
-2.3%
Thin
βš–οΈP/S Ratio
2.4x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$22.64 – $23.31
52-Week Range
$19.16 – $48.25
Volume
$3.34B
Avg Volume
$2.44B
Shares Outstanding
48.5M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$441M
Last Q Revenue
$126M
P/E Ratio
-383.6
P/S Ratio
2.4x
EPS (TTM)
$-0.07
Dividend Yield
0.00%
Dilution (1yr)
+18.4%

Why Investors Own AORT

  • βœ“High-growth profile β€” revenue up +12.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 53% gross margin and 11% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

AORT logo

ARTIVION INC

AORT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$441Mβ–² +13.6% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
61.3%β–Ό βˆ’4.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$27Mβ–Ό βˆ’31.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$911Kβ–Ό βˆ’108.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
49.6Mβ–² +18.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$227Mβ–² +$82M YoY
StockOtter Β· stockotter.space

About ARTIVION INC

Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$27.60
β–² +20.7% Upside
High Target$32.96
Low Target$25.60
Based on 40 analysts

Latest News & Updates

MarketBeatΒ·Aug 7

Artivion Q2 Earnings Call Highlights

Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted E

Seeking AlphaΒ·Aug 7

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript

Zacks Investment ResearchΒ·Aug 6

Artivion (AORT) Q2 Earnings Meet Estimates

Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.

PRNewsWireΒ·Aug 6

Artivion Reports Second Quarter 2026 Financial Results

Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP c

PRNewsWireΒ·Jul 28

Artivion to Participate in Upcoming Investor Conferences

ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences.

PRNewsWireΒ·Jul 23

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT),Β a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on